|Bid||6,791.00 x 0|
|Ask||6,790.00 x 0|
|Day's range||6,763.00 - 6,860.00|
|52-week range||5,312.00 - 8,227.88|
|Beta (3Y monthly)||0.91|
|PE ratio (TTM)||39.56|
|Forward dividend & yield||2.19 (3.21%)|
|1y target est||N/A|
High-quality companies outperform junk companies in the stock market. From Robert Novy-Marx to Joseph Piotroski, the world’s foremost investment academics have8230;
London stocks finished a roller coaster session on Thursday with gains as domestic companies rose after Britain and Ireland said they saw a pathway to a Brexit deal, and international names jumped on to a global rally over hopes of a U.S.-China trade truce. The FTSE 100 ended 0.3% higher, after flipping back and forth during the day on mixed signals over the state of affairs between Beijing and Washington, while the midcap index that has a greater UK exposure also rose by the same level. Spirits company Diageo, consumer goods giant Unilever and AstraZeneca were among stocks hammered the most, causing the FTSE 100 to lag other major indexes.
(Bloomberg) -- Three researchers from the U.S. and Britain won a Nobel Prize for showing how cells sense and adapt to changing oxygen levels, a line of research that’s already led to the development of new drugs.Americans William Kaelin of the Dana-Farber Cancer Institute in Boston and Gregg Semenza of Baltimore’s Johns Hopkins Medicine, and Peter Ratcliffe of the Francis Crick Institute in London received this year’s award for physiology or medicine, the Nobel Assembly at the Karolinska Institute said Monday in a statement.“The seminal discoveries by this year’s Nobel laureates revealed the mechanism for one of life’s most essential adaptive processes,” the assembly said in the statement. “Their discoveries have also paved the way for promising new strategies to fight anemia, cancer and many other diseases.”Semenza and Ratcliffe separately studied the processes surrounding the sensing of oxygen, and found it was at work in virtually all the body’s tissues. Semenza worked in the 1990s on identifying a protein complex that binds to cells’ DNA in response to levels of oxygen in the environment.The complex, called hypoxia inducible factor, regulates production of red blood cells. The science behind it is the basis for an anemia drug codeveloped by AstraZeneca Plc and Fibrogen Inc. called roxadustat that was approved in China in December.Astra is just a few steps away from bringing the drug to patients, said Mene Pangalos, executive vice president of biopharmaceutical research and development, in an email. “This would never have been possible without early breakthroughs of this year’s Nobel winners,” he said.GlaxoSmithKline Plc has filed for Japanese approval of a drug based on the mechanism, called daprodustat. Kaelin’s work linked the same oxygen-regulating machinery to a role in cancer, which is also being mined for potential therapeutics.Annual prizes for achievements in physics, chemistry, medicine, peace and literature were established in the will of Alfred Nobel, the Swedish inventor of dynamite, who died in 1896. The total amount for each of the 2019 prizes is 9 million kronor ($909,000).(Updates with company comment in sixth paragraph)\--With assistance from John Lauerman.To contact the reporters on this story: Niklas Magnusson in Stockholm at firstname.lastname@example.org;Veronica Ek in Stockholm at email@example.comTo contact the editors responsible for this story: Jonas Bergman at firstname.lastname@example.org, ;Tasneem Hanfi Brögger at email@example.com, Eric PfannerFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
With a track record of dividend increases and world-leading positions in their respective markets, these FTSE 100 (INDEXFTSE:UKX) dividend stocks are portfolio essentials.
British drugmaker AstraZeneca said on Friday that the U.S. Food and Drug Administration (FDA) has approved self-administration of its asthma treatment Fasenra which uses a pre-filled, single-use auto-injector pen. The move is a boost for the drugmaker's respiratory portfolio after the regulator earlier this week declined to approve AstraZeneca's combination therapy to treat smoker's lung, as it tries to catch up with domestic rival GlaxoSmithKline. "We can now offer Fasenra in an even more convenient way, giving U.S. healthcare providers and patients the option of administering Fasenra at home or in a doctor's office," Mene Pangalos, executive vice president of BioPharmaceuticals R&D said.
What do you think is the main role of a company’s senior management team? Long-term business strategy? Earnings growth? Or even just making sure the wheels don8230;
I think these two FTSE 100 (INDEXFTSE:UKX) income shares appear to offer favourable prospects when compared to a Cash ISA.
Stock pickers are generally looking for stocks that will outperform the broader market. Buying under-rated businesses...
UK stocks retreated on Tuesday, reversing gains from earlier in the day, coming under pressure following disappointing manufacturing data from the United States that added to concerns about the health of the global economy. The FTSE 100 lost 0.7% and a sub-index of banks fell more than 1%. The main index still outperformed the benchmark European bourse that was already rattled by weak factory activity data from the euro zone.
European shares ended a three-day winning streak on Tuesday as investors were gripped by growth worries after poor U.S. manufacturing data fanned fears of slowing growth in the world's largest economy. The pan-European STOXX 600 index touched session lows, and closed down 1.3% after data showed U.S. manufacturing contracted for the second month in September, knocking U.S. stocks. This followed on from euro zone data that showed manufacturing activity contracting at its steepest rate in almost seven years.
AstraZeneca Plc said on Tuesday it would sell the global commercial rights for its drug to treat acid reflux to German pharmaceutical company Cheplapharm Arzneimittel GmbH for as much as $276 million. Cheplapharm will pay AstraZeneca about $243 million for Losec, a proton pump inhibitor developed by the British drugmaker. The global commercial rights being sold to Cheplapharm, for Losec (omeprazole) and its associated brands, excludes rights in China, Japan, the United States and Mexico, AstraZeneca said.
AstraZeneca said that it will work closely with the FDA regarding next steps, including submitting results from an additional late-stage study, which was not completed at the time the marketing application was submitted to the health regulator. The therapy, PT010, was approved in Japan in June as a triple-combination therapy to relieve symptoms of chronic obstructive pulmonary disease (COPD), AstraZeneca said.
The U.S. Food and Drug Administration declined to approve AstraZeneca Plc's combination therapy to treat smoker's lung, the drugmaker said on Tuesday. AstraZeneca said that it will work closely with the FDA regarding next steps, including submitting results from an additional late-stage study, which was not completed at the time the marketing application was submitted to the health regulator. The therapy, PT010, was approved in Japan in June as a triple-combination therapy to relieve symptoms of chronic obstructive pulmonary disease (COPD), AstraZeneca said.
U.S. stocks climbed on Monday, helped by gains in Apple, Microsoft and Merck & Co, as investors set aside worries about the U.S.-China trade war. Shares of Apple Inc rose 2.4% after Chief Executive Officer Tim Cook told a German daily that sales of the company's newest iPhones were off to a strong start, while JP Morgan raised its forecast for shipment volumes. Apple is struggling to reverse shrinking iPhone sales amid tepid global demand for smartphones.
U.S. 10-year Treasury yield at ~1.68% Sept 30 - Welcome to the home for real-time coverage of U.S. equity markets brought to you by Reuters stocks reporters and anchored today by April Joyner. Reach her on Messenger to share your thoughts on market moves: firstname.lastname@example.org IN WEWORK'S WAKE, IT'S ALL ABOUT BIOTECH IPOS FOR NOW (1400 EDT/1800 GMT) As WeWork officially pulls its IPO, the near-term calendar is chock full of biotech deals.
AstraZeneca presented results on Monday for a trial of its Lynparza drug against prostate cancer, which it hopes could lead to wider regulatory approval for the treatment for use against more forms of the disease. The British drugmaker, together with development partner Merck & Co , said Lynparza was shown to delay disease progression in an aggressive and difficult-to-treat type of prostate cancer by a median 3.8 months in the group most sensitive to the treatment. The data, presented at the annual conference of the European Society for Medical Oncology (ESMO) in Barcelona, adds to further promising results presented on Saturday at the conference that may lead to wider use in women suffering from ovarian cancer.
Shares of AstraZeneca (LON: AZN) are priced for perfection, I believe. But does that make them a good buy for the long term?
The study tested Lynparza in patients as an add-on to an already existing standard of care, bevacizumab, and was compared to a group of patients given bevacizumab alone. The treatment showed a statistically significant and clinically meaningful improvement in progression-free survival in women with newly diagnosed advanced ovarian cancer, the companies said. Lynparza added to bevacizumab reduced the risk of disease progression or death by 41% in the overall trial population.
UK shares were largely unchanged on Monday as investors opted for a wait-and-watch approach amid simmering U.S.-China trade tensions and Brexit worries, and as scant corporate news failed to spur significant stock moves. The exporter-heavy FTSE 100 index was roughly flat, but hovered close to a near two-month high, while the mid-cap index was also flat by 0800 GMT. The FTSE 100 index is on track for its best month since June and the domestically-focussed FTSE 250 was on course for its biggest monthly rise since April.
AstraZeneca Plc and Merck & Co Inc said on Monday their treatment for newly diagnosed advanced ovarian cancer improved progression-free survival in patients tested in a late-stage study. The study tested Lynparza in patients as an add-on to an already existing standard of care, bevacizumab, and was compared to a group of patients given bevacizumab alone. The treatment showed a statistically significant and clinically meaningful improvement in progression-free survival in women with newly diagnosed advanced ovarian cancer, the companies said.
AstraZeneca Plc and Merck & Co Inc said on Monday their drug to treat a form of ovarian cancer improved progression-free survival in patients tested in a late-stage study. The study tested Lynparza in patients as an add-on to an already existing standard of care, bevacizumab, and was compared to a group of patients given bevacizumab alone. Lynparza added to bevacizumab reduced the risk of disease progression or death by 41% in the overall trial population.
GlaxoSmithKline and AstraZeneca both reported trial results that will likely make their competing drugs available to a wider group of ovarian cancer patients, possibly helping GSK catch its rival in a highly contested drug class. The two said separately on Saturday their drug candidates - in a class known as PARP inhibitors - staved off the return of metastasized ovarian cancer in women who had responded to initial standard treatment, reducing the risk of a relapse. AstraZeneca and its U.S. development partner Merck & Co said their Lynparza drug cut the risk of the cancer progressing again by 41%.